Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015).
نویسندگان
چکیده
منابع مشابه
Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
abtract Purpose Drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway show significant clinical activity across several tumor types. However, a majority of patients do not respond to these agents. Use of biomarker assays to predict response to these agents is an active area of research; however, the predictive value of PD-L1 immunohistochemistry (IHC)...
متن کاملThe Role of Caspase 9 during Programmed Cell Death in Ciliary Ganglia of Chick Embryos
During programmed cell death (PCD) apoptosis is controlled by many factors such as proteases. With no specific protease (s) known during PCD in the developing nervous system so far, we sought to determine if any specific protease (s) is involved in this process and therefore used different protease inhibitors during PCD (from embryonic day 6 to 10) in chick embryos. Among the inhibitors commerc...
متن کاملClinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Programmed death 1 (PD-1, CD279) and programmed death ligand 1 (PD-L1, CD274) are involved in generating tumor-associated immunosuppression by suppression of T-cell proliferation and interleukin 2 (IL-2) production and immune checkpoint inhibitors targeting these molecules are showing compelling activity against a variety of human cancers. PD-L1 expression has shown a positive association with ...
متن کاملProgrammed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.
A deeper understanding of the key role of the immune system in regulating tumor growth and progression has led to the development of a number of immunotherapies, including cancer vaccines and immune checkpoint inhibitors. Immune checkpoint inhibitors target molecular pathways involved in immunosuppression, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death pr...
متن کاملFrom monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
Cancer immunotherapy has made an extraordinary journey from bench to bedside. Blocking the interactions between programmed cell death protein 1 (PD-1) and its ligand, PD-L1, has emerged as a promising immunotherapy for treating cancer. Here, we review the development of drugs targeting the PD-1/PD-L1 pathway. We discuss the monoclonal antibodies (mAbs) approved or in clinical trials, peptides a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Expert opinion on therapeutic patents
دوره 26 9 شماره
صفحات -
تاریخ انتشار 2016